Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

On a strong day for the Nasdaq, two highfliers stood out.

If You Thought These 2 Big Nasdaq Winners Were Done, Think Again

Moderna Inc. is adding two new production lines at the rebuilt former Polaroid plant where it manufactures its COVID-19 vaccine, part of a push to prepare for making booster shots and the future of the pandemic

The Wall Street Journal: Moderna plans to expand production of COVID-19 vaccine boosters, supply more countries

GameStop

NVIDIA

Ocugen, Inc.

Palantir Technologies

If analysts are correct, these high-flying stocks will fizzle out over the next year.

5 Ultra-Popular Stocks Wall Street Views as Overvalued

Pfizer

The news continued to be good for mRNA vaccines.

What to Make of the CDC's Latest Efficacy Data on Pfizer's and Moderna's COVID Vaccines

Illumina

Meituan

Baillie Gifford's Tom Slater invests in companies and CEOs with long-term vision, irrespective of short-term market moves.

Moderna, Illumina, or China's Meituan Could Be the Next Tesla, Says This Money Manager

Moderna Inc. said Friday it remains committed to creating jobs in Massachusetts and will hire at least 155 more people for high-tech manufacturing roles this year. The biotech, which has an emergency use authorization for its COVID-19 vaccine, said it has almost doubled its workforce in the Bay State in the past year to about 1,500 workers from 830 as of March 31, 2020.

Moderna to add 155 more people in high-tech manufacturing jobs in Massachusetts in 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna reaffirms commitment to job creation in Massachusetts.

Moderna Reaffirms Commitment to Job Creation in Massachusetts

Moderna stock has been on a roll for several reasons.

The Most Important of Moderna's 3 Catalysts Last Week

Novavax

Good news for one COVID-19 vaccine maker ended up being bad news for all.

Why BioNTech, Moderna, and Novavax Stocks Sank This Week

The U.S. government has placed an order for an additional 200 million doses of mRNA-1273, Moderna, Inc.'s (NASDAQ: MRNA) vaccine against the novel coronavirus, the company said in a statement Wednesday.  The new agreement also carries an option to buy other COVID-19 vaccine candidates from the company's pipeline.

Moderna COVID-19 Vaccine Order Flow Abounds As US Strikes Deal For 200M More Doses

Shares of Moderna Inc. were down 1.2% in premarket trading on Wednesday after the company said the U.S. has agreed to buy an additional 200 million doses of its COVID-19 vaccine. This agreement includes the option to purchase other COVID-19 vaccine candidates that Moderna is developing.

U.S. to buy another 200 million doses of Moderna's COVID-19 vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--The U.S. Government purchases an additional 200 million doses of Moderna's COVID-19 vaccine.

U.S. Government Purchases Additional 200 Million Doses of Moderna's COVID-19 Vaccine

It has to do with leadership in a key area.

Moderna Just Eliminated This 1 Risk

Bionano Genomics

Avid Bioservices

VistaGen Therapeutics

BioCryst Pharmaceuticals

22nd Century Group

Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on InvestorPlace.

7 A-Rated Biotech Stocks to Buy Now

CAMBRIDGE, Mass. and DUBAI, United Arab Emirates--(BUSINESS WIRE)--Moderna and Magenta partner to distribute Moderna's COVID-19 vaccine and updated variant booster candidates in United Arab Emirates.

Moderna and Magenta Partner to Distribute Moderna's COVID-19 Vaccine and Updated Variant Booster Candidates in United Arab Emirates

How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?

ARK Innovation ETF

BigCommerce Holdings, Inc.

Corsair Gaming

The Ark Innovation ETF, Corsair Gaming, BigCommerce and Moderna were our top stock trades. And here's what the charts are telling us now.

4 Top Stock Trades for Tuesday: ARKK, CRSR, BIGC, MRNA

The coronavirus vaccine makers are likely to face intensifying competition.

Why Moderna and BioNTech Stocks Dropped Today

Shares of Moderna Inc. were down 2.1% in premarket trading on Monday after the company said it hired Dr. Paul Burton as its new chief medical officer. Burton, a former Johnson & Johnson executive, will report to CEO Stéphane Bancel.

Moderna hires J&J executive as chief medical officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dr. Paul Burton to join Moderna as Chief Medical Officer.

Dr. Paul Burton to Join Moderna as Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna submits authorization application for its COVID-19 vaccine in adolescents in Switzerland.

Moderna Submits Authorization Application for its COVID-19 Vaccine in Adolescents in Switzerland

Intuitive Surgical

They're gaining this year. But the best may be yet to come.

These 3 Stocks Will Make You Richer in 2021 (and Beyond)

A lot depends on sales in 2022 and beyond.

3 Reasons to Buy Moderna, and 1 Reason to Sell

Moderna Inc (NASDAQ: MRNA) says there is no “causal association” between its COVID-19 vaccine and cases of myocarditis or pericarditis, based on a review of safety data. The Centers for Disease Control and Prevention (CDC) has identified 216 cases of heart inflammation after the first dose of an mRNA shot and another 573 cases after the second dose, Bloomberg reported.

Moderna Says No Link Between COVID-19 Jab And Heart Inflammation

The company said it made the conclusion after "carefully reviewing the available safety data to date for Moderna COVID-19 Vaccine."

News for Moderna Stock (MRNA)